The Market Signal was created as a platform to help investors, if you own (NASDAQ:VRA), (NASDAQ:JNCE) or (NASDAQ:AKCA) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.
https://themarketsignal.com/Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)
Vera Bradley is positive following record revenue from the sale of face masks
https://themarketsignal.com/Free-Report/VRA
(Click link above or copy, paste and hit enter in your browser for your report)
Vera Bradley, Inc (NASDAQ:VRA) is currently trading 52.49% above its 20 Days simple moving average and the stock looks bullish
Vera Bradley, Inc has raised a total of $633,636 that will be donated to the American Nurses Foundation's Coronavirus Response Fund. The funds were raised from the sale of mask from July this year. The Fort Wayne-based company shifted to production of PPEs in the wake of the COVID-19 pandemic. The company has supplied more than 5 million face masks to frontline workers.
Jounce Therapeutics is bullish following exclusive licencing agreement with Jounce Therapeutics
https://themarketsignal.com/Free-Report/JNCE
(Click link above or copy, paste and hit enter in your browser for your report)
Jounce Therapeutics Inc (NASDAQ:JNCE) is currently trading 50.00% above its 20 Days simple moving average and the stock looks bullish
Gilead Sciences has signed an agreement with Jounce Therapeutics seeking exclusive license of its JTX-1811 program. JTX-1811 is Gilead Sciences' monoclonal antibody being developed to cure immunosuppressive tumor-infiltrating T regulatory (TITR) cells. JTX-1811 works by attacking a chemokine receptor called CCR8 and which attaches itself to TITR cells. Under the agreement, Gilead will pay a down payment of $85 million plus an equity investment of $35 million. Jounce will also get an additional $685 million future clinical, regulatory and commercial milestone payments.
Akcea Therapeutics is bullish as it commences pricing renegotiation
https://themarketsignal.com/Free-Report/AKCA
(Click link above or copy, paste and hit enter in your browser for your report)
Akcea Therapeutics Inc. (NASDAQ:AKCA) is currently trading 49.65% above its 20 Days simple moving average and the stock looks bullish
Akcea Announces New Pricing and Reimbursement of WAYLIVRA(R) (volanesorsen) in Germany
Akcea Therapeutics has struck a new pricing and reimbursement agreement with German Association of Statutory Sick Funds for WAYLIVRA(R) (volanesorsen). The product is being developed to cure chylomicronemia syndrome (FCS) in adult patients. WAYLIVRA was first approved for sale in Germany in August 2019.
Please email or contact us for any edits or errors relating to this stock market news.
If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.
We will get back to you within 24 hours.
COMTEX_370624321/2700/2020-09-03T06:57:15
Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.
